News about Global Pharma

Endo Expands ADRENALIN RTU Premixed Bag Portfolio with New Concentration Option

Endo, Inc. has announced the launch of an FDA-approved ADRENALIN, currently the only commercially available manufacturer-prepared epinephrine premixed intravenous (IV) bag.

Global Pharma | 17/05/2025 | By Manvi |  215

ISSS Endorses Hyoid Suspension as Safe, Effective Treatment for Obstructive Sleep Apnea

Following a rigorous review of clinical research, the International Surgical Sleep Society (ISSS) recently published a position statement supporting hyoid suspension as a safe and effective approach in the medical and surgical management of obstructive sleep apnea (OSA).

Global Pharma | 17/05/2025 | By Manvi |  483

Maness Veteran Medical's NEUBIE Device Now Available to VA, DoD via Federal Supply Schedule

Maness Veteran Medical (MVM) announce a major step forward in the future of veteran care: the NEUBIE (Neuro-Bio-Electric Stimulator) device is now officially available through the Federal Supply Schedule (FSS), contract 36F79725D0083.

Global Pharma | 17/05/2025 | By Manvi |  336

Sun Pharma Secures FDA Approval for Next-Generation BLU-U Blue Light Therapy Device for Actinic Keratosis

Sun Pharma has received FDA approval for its next-generation LED BLU-U Blue Light Photodynamic Therapy Illuminator for treating actinic keratosis.

Global Pharma | 17/05/2025 | By Manvi |  519

Nordic Bioscience Introduces Novel Endotrophin Assay

Nordic Bioscience has launched nordicEndotrophin, a fully automated, high-precision assay that quantifies the intact 77-amino-acid Endotrophin hormone, enhancing risk stratification and treatment monitoring in fibrosis, cancer, and chronic diseases.

Global Pharma | 16/05/2025 | By Manvi |  166

Senores Pharmaceuticals Reports 174 Percent Revenue Growth in Emerging Markets in FY25

Senores Pharmaceuticals Ltd. reported a robust 69 percent year-on-year growth in regulated market revenue to INR 244.8 crore in FY25, alongside a 174 percent surge in emerging market revenue, reflecting strong momentum across its global pharmaceutical operations.

Global Pharma | 16/05/2025 | By Manvi |  423

Wesper Revolutionizes Sleep Apnea Diagnosis with FDA-Cleared, Cannula-Free Technology

Without capturing this core signal, critical events like hypopneas can be missed, misclassified, or misunderstood. As clinical research and expert consensus increasingly affirm, airflow isn't optional—it's essential.

Global Pharma | 16/05/2025 | By Manvi |  294

Marksans Pharma's UK Subsidiary Relonchem Secures Marketing Authorisation for Gabapentin from UKMHRA

Relonchem Ltd. has received marketing authorisation for its product Gabapentin 50 mg/ml oral solution.

Global Pharma | 15/05/2025 | By Manvi |  276

Sanofi to Invest USD 20 Billion in US by 2030 to Expand R&D and Manufacturing

Sanofi has announced plans to invest at least $20 billion in the United States by 2030, significantly boosting R&D and manufacturing to support the launch of new therapies and strengthen the domestic supply chain.

Global Pharma | 15/05/2025 | By Manvi |  191

Genesys Spine Launches Stasys-C 3DP, a Zero-Profile 3D-Printed Cervical Standalone System

Genesys Spine has announced the commercial launch of the Stasys-C™ 3DP Cervical Standalone System, a 3D-printed, zero-profile cervical interbody solution designed to simplify anterior cervical procedures while promoting early fusion.

Global Pharma | 15/05/2025 | By Manvi |  188